Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma

被引：39
|
作者：
Allmeroth, Kira [1 ]
Horn, Moritz [2 ]
Kroef, Virginia [1 ]
Miethe, Stephan [1 ]
Mueller, Roman-Ulrich [3 ,4 ,5 ,6 ]
Denzel, Martin S. [1 ,3 ,6 ]
机构：
[1] Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany
[2] Acus Labs GmbH, Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany
[3] Univ Cologne, CECAD Cluster Excellence, Joseph Stelzmann Str 26, D-50931 Cologne, Germany
[4] Univ Cologne, Fac Med, Dept Internal Med 2, Kerpener Str 62, D-50937 Cologne, Germany
[5] Univ Cologne, Univ Hosp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
[6] Univ Cologne, Ctr Mol Med Cologne CMMC, Robert Koch Str 21, D-50931 Cologne, Germany
来源：
LEUKEMIA | 2021年 / 35卷 / 03期
关键词：
20S PROTEASOME;
D O I：
10.1038/s41375-020-0989-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：887 / 892
页数：6
相关论文
共 48 条
  • [41] Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
    Driessen, Christoph
    Kraus, Marianne
    Joerger, Markus
    Rosing, Hilde
    Bader, Jurgen
    Hitz, Felicitas
    Berset, Catherine
    Xyrafas, Alexandros
    Hawle, Hanne
    Berthod, Gregoire
    Overkleeft, Hermann S.
    Sessa, Christiana
    Huitema, Alwin
    Pabst, Thomas
    von Moos, Roger
    Hess, Dagmar
    Mey, Ulrich J. M.
    HAEMATOLOGICA, 2016, 101 (03) : 346 - 355
  • [42] A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors
    De Santis, Sara
    Monaldi, Cecilia
    Martelli, Margherita
    Mancini, Manuela
    Bruno, Samantha
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Polakova, Katerina Machova
    Ernst, Thomas
    Maar, Dianna
    Corner, Adam
    Cavo, Michele
    Soverini, Simona
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S289 - S290
  • [43] Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma
    Inoue, Yasumichi
    Hikami, Koki
    Ebara, Shunsuke
    Sugiyama, Midori
    Oda, Robert
    Mizutani, Akio
    Yoshida, Misaki
    Yamakawa, Hiroko
    Yagishita, Shigehiro
    Hamada, Akinobu
    Hayashi, Hidetoshi
    Ri, Masaki
    Iida, Shinsuke
    Morishita, Daisuke
    CANCER RESEARCH, 2024, 84 (06)
  • [44] Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors
    Hachiya, Atsuko
    Kirby, Karen A.
    Ido, Yoko
    Shigemi, Urara
    Matsuda, Masakazu
    Okazaki, Reiko
    Imamura, Junji
    Sarafianos, Stefan G.
    Yokomaku, Yoshiyuki
    Iwatani, Yasumasa
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)
  • [45] Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors
    Menzel, Michael
    Kirchner, Martina
    Kluck, Klaus
    Ball, Markus
    Beck, Susanne
    Allgaeuer, Michael
    Assmann, Christin
    Schnorbach, Johannes
    Volckmar, Anna-Lena
    Tay, Timothy Kwang Yong
    Goldschmid, Hannah
    Tan, Daniel S. W.
    Thomas, Michael
    Kazdal, Daniel
    Budczies, Jan
    Stenzinger, Albrecht
    Christopoulos, Petros
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2024, 10 (02):
  • [46] Vactosertib, a TGF-β Receptor I Kinase/ALK5 Inhibitor, Diminishes Tumor Progression and Bone Disease in a Mouse Model of Multiple Myeloma and Overcomes Resistance to Proteasome Inhibitors
    Kim, Byung-Gyu
    Choi, Sung Hee
    Luo, George
    Sergeeva, Olga
    Lee, Zhenghong
    Driscoll, James
    de Lima, Marcos
    Beck, Rose
    Kim, Seong-Jin
    Letterio, John
    Malek, Ehsan
    BLOOD, 2018, 132
  • [47] Brief report Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile
    Parker, Wendy T.
    Ho, Musei
    Scott, Hamish S.
    Hughes, Timothy P.
    Branford, Susan
    BLOOD, 2012, 119 (10) : 2234 - 2238
  • [48] Influence of Genetic Polymorphisms in CYP1A2, CYP2C19, CYP3A4, GSTP1, MDR1 and PSMB5 Genes in Toxicity and Response to Induction Therapy in Multiple Myeloma Patients Included in the Trial of the Spanish PETHEMA/GEM 05 for Newly Diagnosed MM Elderly Patients (Age 65 or More)
    Castilla-Llorente, Cristina
    de Arriba, Felipe
    Perez-Andreu, Virginia
    Victoria Mateos, Maria
    Gonzalez-Conejero, Rocio
    Rivera Pozo, Jose
    Oriol, Albert
    Martinez-Lopez, Joaquin
    Isabel Teruel, Ana
    de Paz, Raquel
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martin, Alejandro
    Diaz-Mediavilla, Joaquin
    Palomera, Luis
    Gonzalez, Yolanda
    Mariano Hernandez, Jose
    Sureda, Anna
    Luis Bello, Jose
    Bargay, Joan
    Javier Penalver, Francisco
    Martin Mateos, Maria Luisa
    Teresa Cibeira, Maria
    Jose Lahuerta, Juan
    Blade, Joan
    San Miguel, Jesus F.
    BLOOD, 2011, 118 (21) : 615 - 615
12345